Chronic Levodopa (l-DOPA), the gold standard therapy for Parkinson's disease (PD), causes disabling motor complications (dyskinesias) that are associated with changes in the activity of striatal protein kinase A (PKA) and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). In this study, we showed that systemic administration of the cannabinoid agonist WIN55212-2 ameliorated l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-OHDA rat model of PD and reversed l-DOPA-induced PKA hyperactivity via a CB 1 -mediated mechanism. This effect was accompanied by increased phosphorylation of DARPP-32 at threonine 34, which was partially blocked by CB 1 antagonism. Striatal PKA activity was positively correlated with the severity of l-DOPA-induced axial and limb dyskinesias, suggesting a role for the cAMP/PKA signaling pathway in the expression of these motor disturbances.
Parkinson's disease c-AMP-regulated phosphoprotein 32 Striatum CB1 receptor Cannabinoid Dopamine Dyskinesia a b s t r a c t Chronic Levodopa (l-DOPA), the gold standard therapy for Parkinson's disease (PD), causes disabling motor complications (dyskinesias) that are associated with changes in the activity of striatal protein kinase A (PKA) and cAMP-regulated phosphoprotein of 32 kDa . In this study, we showed that systemic administration of the cannabinoid agonist WIN55212-2 ameliorated l-DOPA-induced abnormal involuntary movements (AIMs) in the 6-OHDA rat model of PD and reversed l-DOPA-induced PKA hyperactivity via a CB 1 -mediated mechanism. This effect was accompanied by increased phosphorylation of DARPP-32 at threonine 34, which was partially blocked by CB 1 antagonism. Striatal PKA activity was positively correlated with the severity of l-DOPA-induced axial and limb dyskinesias, suggesting a role for the cAMP/PKA signaling pathway in the expression of these motor disturbances.
Our results indicate that activation of CB 1 receptors, as well as reduction of striatal PKA hyperactivity, might be an effective strategy for the treatment of l-DOPA-induced dyskinesias.
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Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by severe motor impairment resulting from the loss of dopaminergic nigro-striatal neurons. The dopamine precursor 3,4-dihydroxyphenyl-l-alanine (l-DOPA) is the gold standard treatment to control PD symptoms in the initial phase of the disease. However, its therapeutic efficacy wanes with time, and development of "on"/"off" phenomena and disabling chorealike involuntary movements, termed l-DOPA-induced dyskinesias (LID), have been reported in the majority of PD patients chronically treated with l-DOPA (Fahn, 2006) . LID can be modeled via chronic administration of low doses of l-DOPA to rats with unilateral 6-hydroxydopamine (6-OHDA) lesions. This regimen produces increasingly severe abnormal involuntary movements (AIMs) resembling the dyskinetic symptoms observed in PD patients (Lundblad et al., 2002) . LID development and expression have been linked to several alterations in the basal ganglia circuitry, including increased responsiveness of striatal medium spiny neurons (MSN) to dopamine (Bezard et al., 2001; Olanow and Obeso, 2000) , pulsatile stimulation of dopamine receptors (Obeso et al., 2004) , changes in l-DOPA and dopamine bioavailability (Carta et al., 2006; de la Fuente-Fernandez et al., 2004) , dopamine release from serotonin terminals (Carta et al., 2008) , increased dopamine D1 receptor-mediated signaling (Bezard et al., 2001 ) and maladaptive changes in synaptic plasticity (Cenci and Lundblad, 2006; Picconi et al., 2003; Kreitzer and Malenka, 2007) . In addition, several studies have shown an association between the development of l-DOPA-induced abnormal motor responses and dysregulation of the cAMP/protein kinase A (PKA) signaling cascades, and of the dopamine-and cAMP-regulated phosphoprotein-32 kDa (DARPP-32) (Oh et al., 1997; Picconi et al., 2003; Santini et al., 2007) . DARPP-32 is highly expressed in MSN and its activity is regulated via two phosphorylation sites, threonine (Thr)-34 and Thr-75. PKA-mediated phosphorylation of Thr-34 converts DARPP-32 into an inhibitor of protein phosphatase 1 (PP1) (Hemmings et al., 1984) , whereas phosphorylation at Thr-75 promotes inhibition of PKA activity (Bibb et al., 1999) .
Experimental evidence points to the endocannabinoid system as a novel pharmacological target to treat LID, and either pharmacological blockade (Segovia et al., 2003; van der Stelt et al., 2005) or activation (Morgese et al., 2007; Papa, 2008) of cannabinoid CB 1 receptors has been associated with beneficial effects on LID. CB 1 receptors are expressed in brain areas regulating motor function, including the basal ganglia, cerebellum and sensory-motor
